Dysregulated Mitochondrial Genes and Networks with Drug Targets in Postmortem
     Brain of Patients with Posttraumatic Stress Disorder (PTSD) Revealed by Human
     Mitochondria-Focused cDNA Microarrays by Su, Yan A. et al.
Int. J. Biol. Sci. 2008, 4 
 
223
International Journal of Biological Sciences 
ISSN 1449-2288 www.biolsci.org 2008 4(4):223-235 
© Ivyspring International Publisher. All rights reserved 
Research Paper 
Dysregulated Mitochondrial Genes and Networks with Drug Targets in 
Postmortem Brain of Patients with Posttraumatic Stress Disorder (PTSD) 
Revealed by Human Mitochondria-Focused cDNA Microarrays 
Yan A. Su1, Jun Wu1, Lei Zhang2, Qiuyang Zhang1, David M. Su1, Ping He3, Bi-Dar Wang1, He Li2, Maree J. 
Webster4, Traumatic Stress Brain Study Group, Owen M. Rennert5, and Robert J. Ursano2 
1.  Department of Biochemistry and Molecular Biology and the Catherine Birch McCormick Genomics Center, The George 
Washington University School of Medicine and Health Sciences, Washington, DC, 20037; 
2.  Department of Psychiatry and Center for the Study of Traumatic Stress, Uniformed Services University of the Health 
Sciences, Bethesda, MD 20814; 
3.  Division of Hematology, Center for Biological Evaluation and Research, Food and Drug Administration, Bethesda, MD 
20892; 
4.  Stanley Medical Research Institute, Chevy Chase, MD 20894; 
5.  Laboratory of Clinical Genomics, National Institute of Child Health and Human Development, National Institutes of 
Health, Bethesda, MD 20892;  
Correspondence to: Yan A. Su, MD and PhD, Ross Hall, Room 555, 2300 I St., NW, Washington, DC 20037; Tel: 202-994-1891; Fax: 
202-994-8974; Email: bcmyas@gwumc.edu 
Received: 2008.06.24; Accepted: 2008.08.02; Published: 2008.08.05 
Posttraumatic stress disorder (PTSD) is associated with decreased activity in the dorsolateral prefrontal cortex 
(DLPFC), the brain region that regulates working memory and preparation and selection of fear responses. We 
investigated gene expression profiles in DLPFC Brodmann area (BA) 46 of postmortem patients with (n=6) and 
without PTSD (n=6) using human mitochondria-focused cDNA microarrays. Our study revealed PTSD-specific 
expression fingerprints of 800 informative mitochondria-focused genes across all of these 12 BA46 samples, and 
119 (±>1.25, p<0.05) and 42 (±>1.60, p<0.05) dysregulated genes between the PTSD and control samples. Quanti-
tative RT-PCR validated the microarray results. These fingerprints can essentially distinguish the PTSD DLPFC 
BA46 brains from controls. Of the 119 dysregulated genes (±≥125%, p<0.05), the highest percentages were asso-
ciated with mitochondrial dysfunction (4.8%, p=6.61x10-6), oxidative phosphorylation (3.8%, p=9.04x10-4), cell 
survival-apoptosis (25.2%, p<0.05) and neurological diseases (23.5%, p<0.05). Fifty (50) dysregulated genes were 
present in the molecular networks that are known to be involved in neuronal function-survival and contain 7 
targets for neuropsychiatric drugs. Thirty (30) of the dysregulated genes are associated with a number of neuro-
psychiatric disorders. Our results indicate mitochondrial dysfunction in the PTSD DLPFC BA46 and provide the 
expression fingerprints that may ultimately serve as biomarkers for PTSD diagnosis and the drugs and molecular 
targets that may prove useful for development of remedies for prevention and treatment of PTSD. 
Key words: PTSD; Brain dorsolateral prefrontal cortex BA46; Gene expression pattern; Biomarker; Mitochondria; Canonical 
pathways; Molecular networks; Neuropsychiatric drug targets 
Introduction 
Posttraumatic Stress Disorder (PTSD) is a com-
plex mental disorder that can develop in response to a 
traumatic event such as a motor vehicle accident, rape, 
combat exposure or natural disaster. The National 
Vietnam Veterans Readjustment Study estimated that 
53.4% of US male veterans of the Vietnam war devel-
oped full or partial PTSD and 15.2% still suffered from 
the disorder in 1990 [1]. The application of conserva-
tive procedures for analysis led Dohrenwend et al to 
document that 18.7% of male veterans developed 
war-related PTSD during their life time and 9.1% were 
still suffering from PTSD 11 to 12 years after the war 
[2]. In the general population, the estimated lifetime 
prevalence of PTSD is 7.8% in adult Americans, with 
women having a 2.3-fold higher prevalence than men 
[3]. PTSD symptoms include intrusive thoughts, hy-
perarousal, nightmares, flashbacks, emotional de-
tachment or numbing of feelings, insomnia, fear, Int. J. Biol. Sci. 2008, 4 
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avoidance of reminders, distress when exposed to re-
minders, irritability, hypervigilance, and heightened 
startle response [4]. 
Several lines of evidence support neurochemical, 
functional and structural alterations in the neuroen-
docrine system in patients with PTSD. The neuro-
chemical alterations range from adrenergic hyperre-
sponsiveness, increased thyroid activity, increased 
levels of corticotrophin-releasing factor, to low cortisol 
levels and increased negative feedback sensitivity of 
the hypothalamo-pituitary-adrenal-axis after the ad-
ministration of low-dosage dexamethasone [5]. Func-
tional brain imaging studies in patients with PTSD 
demonstrate increased function in the amygdala and 
decreased activity in the hippocampus and prefrontal 
cortex (PFC) [6;7]. These functional alterations are 
consistent with the structural findings in animal mod-
els of PTSD that neurons in the hippocampus and PFC 
display atrophy while those in amygdala show growth 
in response to repeated stress [8].  
DLPFC including BA46 is one of the three regions 
of PFC, which regulates working memory and execu-
tion of fear responses [9]. This brain region has been 
correlated with structural and functional alterations, 
and with the treatment response of patients with 
PTSD. In children with PTSD symptoms, decreased 
volume of gray matter in the DLPFC is correlated with 
increased functional impairment [10]. Adult patients 
with PTSD core symptoms (i.e. re-experiencing, 
avoidance) were markedly improved by treatment 
with 10-Hz repetitive transcranial magnetic stimula-
tion over the right DLPFC [11]. Furthermore, the indi-
cator of neuronal viability, N-acetylaspartate, in 
DLPFC was correlated positively in healthy people 
with verbal intelligence [12], and negatively in patients 
with a generalized anxiety disorder following a pre-
vious traumatic event [13].  
Although the prefrontal cortex, amygdala and 
hippocampus are the brain regions considered to be 
related to PTSD [6;7], the underlying molecular 
mechanisms are unknown. One of the possibilities is 
that functional and structural changes in the brain may 
result from mitochondria-centered responses to re-
peated or chronic harmful stresses [14;15]. Mitochon-
dria provide the cell with energy in the form of ATP 
and play fundamental roles in many metabolic path-
ways, such as β-oxidation, the tricarboxylic acid cycle 
and urea cycle, the synthesis of steroid hormones and 
heme, and calcium signaling. In addition, mitochon-
drial biochemical and molecular pathways are a natu-
ral central target of diverse pharmacological agents 
[16]. However, reactive oxygen species (ROS), an in-
evitable by-product of mitochondrial oxidative phos-
phorylation, can impair molecules, contributing to 
various diseases including neurodegeneration [17]. 
Thus, homeostasis of these mitochondrial functions is 
critical in human brain because of its high energy de-
mand. 
Mitochondrial dysfunctions are increasingly 
recognized as key components in stress related mental 
disorders [14;15]. Although long or repetitive exposure 
to stress can induce a neurological change resulting in 
PTSD, the molecular pathology involving in such a 
neuronal damage remain elusive. Psychological stress 
was associated with oxidative stress and telomere 
shortening [18]. Overexpression of antioxidant en-
zymes (glyoxalase and glutathione reductase 1) in 
mouse brain was also associated with increase in anx-
ious behavior [19]. In addition, chronic stress of rats 
inhibits the activities of mitochondrial respiratory 
complexes (inhibition of 69% in complex I-III and of 
67% in complex II-III) [20]. Cortisol has widespread 
functions including activation of glucocorticoid 
receptor which bind directly to mitochondrial mem-
brane and regulate apoptosis [15]. The steroidogenic 
acute regulatory protein is one of the outer mitochon-
drial membrane protein required for stress responses 
[21]. Although all these studies indicate mitochondrial 
dysfunction, they are all focusing on a specific candi-
date gene(s). The lack of a holistic study of all the mi-
tochondria-related genes hinders the progress of the 
PTSD research. 
To date, methods employing a systems biology 
approach to identify the mitochondria-focused genes 
underlying the pathogenesis in PTSD-related brain 
regions have not been documented, probably due to 
the lack of human postmortem brain tissue from PTSD 
patients. The expression signatures in blood cells have 
been associated with changes in peripheral lympho-
cytes of subjects with PTSD [22;23], but provide no 
information for molecular abnormalities in brain tis-
sues. Here we report the identification of expression 
signatures, canonical pathways, molecular networks 
and drug targets of dysregulated neuropsychiatric 
disease-related genes in BA46 of postmortem brain 
tissue from patients with PTSD using a human mito-
chondria-focused cDNA microarray (hMitChip3) [24]. 
Our results indicate mitochondrial dysfunction in the 
DLPFC BA46 and may prove useful for developing 
methods for diagnosis and treatment of PTSD. 
Materials and Methods 
Postmortem Brain Tissue: Postmortem brain 
tissues were collected by the Traumatic Stress Brain 
Study Group who diagnosed, collated, planned, coor-
dinated, made decisions on inclusion and exclusion, 
established procedures of diagnosis and interrogated 
reliability, and obtained normal brains for controls as Int. J. Biol. Sci. 2008, 4 
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well. Medical records were meticulously reviewed and 
clinical diagnoses were confirmed using DSM-IV cri-
teria [4]. Table 1 lists all available brain tissues em-
ployed for this study, with some clinical data including 
patient’s gender and age (≤4-year difference), brain pH 
(≤0.65 difference) and reasons of death. Eight subjects 
died from myocardial infarction/heart attack, two 
from suicide by overdose, one from alcoholism com-
plications and another from pulmonary embolism. The 
brain pH was determined from homogenized brain 
occipital cortex tissue. Tissue (0.4-0.8g) was thawed 
and homogenized in 10 times the tissue volume of 
deionized distilled H2O and the homogenate pH was 
measured with the PerpHect pH 370 model meter with 
a compatible PerpHect sure-flow type probe (ATI 
Orion, Boston, MA, USA). The pH electrode was 
washed thoroughly in deionized distilled H2O after 
each sample and recalibrated at the standard 3 points 
of pH (4, 7, and 10).  
Table 1. Demographic Data for Autopsy Cases 
Case  Sex  Age (yr) PMI (hr) Brain PH Cause of Death
PTSD Patients           
 P_1  F  39  39  6.45  SUIC/OD 
 P_2  F  40  38  6.35  SUIC/OD 
 P_3  F  42  36  6.58  CARDIAC 
 P_4  F  44  46  6.56  CARDIAC 
 P_5  F  47  46  6.77  ALC/COM 
 P_6  M  54  86  6.77  CARDIAC 
Control Subjects          
 N_1  F  35  40  5.80  PUL/EMB 
 N_2  F  39  24  6.88  CARDIAC 
 N_3  F  44  25  6.30  CARDIAC 
 N_4  F  44  28  6.59  CARDIAC 
 N_5  F  44  10  6.20  CARDIAC 
 N_6  F  56  29  6.78  CARDIAC 
PMI: postmortem interval; SUIC/OD: suicide by overdose; 
CARDIAC: myocardial infarction/heart attack; ALC/COM: alco-
holism complications; PUL/EMB: pulmonary embolism. 
 
RNA Preparation: DLPFC BA46 tissues were 
dissected from postmortem brains and the samples 
contained primarily gray matter with small but ran-
dom amount of white matter because the dissections 
were done from frozen tissue blocks but not from cry-
ostat sections. Total RNA was isolated using TRIZOL 
reagents (Invitrogen Inc. Carlsbad, CA, USA) and then 
purified with RNeasy kit (Qiagen, Valencia, CA), fol-
lowing the manufacture’s instructions.  
hMitChip3 Gene Chip and Microarray Data 
Analysis: A third-generation human mitochon-
dria-focused cDNA microarray (hMitChip3) contain-
ing 37 mitochondrial DNA-encoded genes, 1,098 nu-
clear DNA-encoded and mitochondria-related genes 
and 225 controls was printed as described previously 
[24]. A total of 1135 mitochondria-related genes in-
clude 946 genes associated with 645 molecular func-
tions, 930 genes with 612 biological processes, 476 
genes with biological chemistry pathways, 227 genes 
with 23 reactome events, 237 genes with 320 genetic 
disorders, and 55 genes with 87 drugs targets[24]. For 
examples, 89 genes are related to oxidative phos-
phorylation, 20 genes to apoptosis, and 14 genes to 
neurotransmitter (tyrosine, L-dopa and dopamine) 
metabolism. Five μg of RNA per sample were used for 
microarray labeling and hybridization as previously 
described [24]. Slides were scanned using the ScanAr-
ray Express Microarray Scanner (PerkinElmer, Boston, 
MA, USA) as described previously [24]. Microarray 
database construction, data filtering and normalization 
were performed as described previously [24;25]. The 
normalized data were used to cluster and visualize 
expression levels of genes in these brain tissue speci-
mens by using Eisen’s Cluster software [26]. Heat map 
was visualized by using Eisen’s Maple Tree software 
(http://rana.lbl.gov/EisenSoftware.htm). 
Gene Information Analysis: Gene ID, symbols 
and names were derived from human UniGene Build 
204 (ftp://ftp.ncbi.nih.gov/repository/UniGene/) 
based on human cDNA I.M.A.G.E. clone ID 
(http://image.llnl.gov/). Ontology, pathways and 
phenotypes of genes were compiled from Entrez 
(ftp://ftp.ncbi.nlm.nih.gov/gene) and DAVID Bioin-
formatics Resources 2008 
(http://david.abcc.ncifcrf.gov/). Ingenuity Pathway 
Analysis software IPA version 6.0 (Ingenuity Systems 
Inc., Redwood City, CA, USA) was used to map ca-
nonical pathways, diseases, disorders, molecular net-
works and drug targets and to calculate the percent-
ages and p-values (Fisher exact test). The reference 
gene set in canonical pathway was within the software. 
Quantitative RT-PCR (qRT-PCR): Two μg of to-
tal RNA was reverse-transcribed into cDNA by using 
SuperScript TM First-Strand Synthesis System (Invitro-
gen). 30 ng cDNA was used for qPCR reactions with 
the Universal PCR Master Mix (No AmpErase UNG) 
on an Applied Biosystems 7300 Real Time PCR System 
(Foster City, CA, USA), following the manufacturer’s 
instructions. After 40 cycles, data reduction was per-
formed with the 7300 PCR Software. Triplicate 
qRT-PCR experiments were performed for each gene. 
Relative RNA concentrations were calculated using the 
published methods[27;28]. TaqMan probes and prim-
ers for qPCR were purchased from Applied Biosys-
tems and include those of glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH, 4352934E), DnaJ (Hsp40) 
homolog subfamily C member 19 (DNAJC19, 
Hs00829488_s1), solute carrier family 1 (high affinity 
aspartate/glutamate transporter) member 6 (SLC1A6, 
Hs00192604_m1), solute carrier family 9 (so-
dium/hydrogen exchanger) member 6 (SLC9A6, Int. J. Biol. Sci. 2008, 4 
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Hs00234723_m1), amyloid beta (A4) precursor protein 
(APP, Hs00169098_m1), and estrogen receptor 2 (ER 
beta) (ESR2, Hs00230957_m1). 
Statistics: Statistical calculations were performed 
on triplicate array experiments using XLSTAT 2006 
(XLSTAT, New York, NY, USA). Differentially ex-
pressed genes were identified arbitrarily by ≥1.25-fold 
change in the average expression of the back-
ground-subtracted mean intensity ratios of a gene 
between PTSD and control, with p-value <0.05. Stu-
dent t-test was used to calculate p-values for gene ex-
pression, while Fisher exact test in Ingenuity Pathway 
Analysis software was used to calculate p-values for 
pathways and diseases. The level of statistical signifi-
cance was set at a p-value <0.05. 
RESULTS 
Expression clusters of mitochondria-focused 
genes distinguished the PTSD and control brains. 
Table 1 lists demographic data for autopsy cases used 
for this study. Total RNA samples were extracted from 
gray matter that was dissected from postmortem brain 
DLPFC BA46 of PTSD brains (n=6) and unaffected 
controls (n=6) and labeled for triplicate microarray 
experiments using our recently developed third gen-
eration human mitochondria-focused cDNA microar-
ray hMitChip3. Because use of 3 replicates in cDNA 
microarrays analysis of even a single specimen greatly 
reduces misclassification rates [29], the hMitChip3 
genes were all measured 9 times (3 identical probes per 
microarray and 3 microarray experiments per speci-
men), which generated reliable expression data for 
further analysis. The microarray data of 4,080 spots 
across all 36 gene chips used for 12 RNA samples were 
filtered by uniform statistic and bioinformatic criteria 
as described previously [24;30], which generated 800 
genes with informative expression profiles. The sup-
plemental table 1 reports the expression data of the 
selected 800 genes in each of the triplicate experiments 
before and after normalization as the raw and proc-
essed data, respectively; while Figure 1 shows the box 
plots of mRNA levels of 800 genes before and after the 
data normalization. The normalized data were used 
for unsupervised clustering analysis and visualization. 
The resultant dendrograms for all of these 800 genes 
and 12 brain DLPFC BA46 specimens classified P1, P2, 
P3, P5, P6 and N2 in one group and N1, N3, N4 N5, N6 
and P4 in another (Fig. 2A and Supplemental Figure 1); 
these analysis separated the PTSD brain from the con-
trol except for N2 and P4 (opposite from their clinical 
diagnosis). 
 
Fig 1. Box plots of expression data before and after normalization. The quantile normalization algorithms[25] were used to 
adjust the values of the background-subtracted mean pixel intensities of each and every set of 800 genes that were selected from the 
hMitChip3 triplicate microarray experiments hybridized with PTSD and control prefrontal cortex RNA samples as described pre-
viously[24]. In contrast to the pre-normalization boxplots (top panel), the post-normalized boxplots distribute in the same intervals 
with the same density center, indicating successful adjustment of data. The post-normalized data were used for clustering analysis. 
S-E: Sample and independent microarray experiment. 
 Int. J. Biol. Sci. 2008, 4 
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  Fig 2. Dendrograms and heat maps of gene expression in 
human brain DLPFC BA46 tissue samples. (A) Dendro-
gram of unsupervised cluster of the PTSD and control DLPFC 
BA46 tissue samples based on expression similarities of 800 
human mitochondria-focused genes (Supplemental Table 1); 
(B) Dendrograms and heat maps of 119 (±≥1.25, p<0.05) and 
(C) 42 (±≥1.60, p<0.05) dysregulated genes across all of these 
12 BA46 samples. The results revealed the PTSD (P) and 
non-PTSD (N) groups. The control case N2 is clustered in the 
PTSD group, while the PTSD case P4 in the control group. 
Green: down-regulation; red: up-regulation; black: no change. 
The case numbers and gene symbols are indicated. The color 
map indicates degrees of up- and down-regulation of gene 
expression. 
Based on the unsupervised cluster results, we 
calculated an average expression level of each gene 
in the PTSD group (P1, P2, P3, P5, P6 and N2) and in 
the non-PTSD control group (N1, N3, N4 N5, N6 and 
P4). The ratios and p-values (t-test) were calculated 
between the PTSD and control specimens, resulting 
in the identification of 119 genes (p<0.05, ±≥1.25) and 
42 genes (p<0.05, ±≥1.60) whose expression were 
dysregulated in the PTSD DLPFC BA46 as compared 
to the controls (Supplemental Table 2). Clustering 
analysis of these 119 and 42 genes across all 12 brain 
samples generated double dendrograms and heat 
maps that clearly distinguish the PTSD DLPFC BA46 
specimens from the controls (Fig. 2B and 2C). The 
identification of these dysregulated genes provides 
candidates with biological clues for validation of 
mRNA expression and future functional studies. 
qRT-PCR confirmation of microarray results. 
T o  v a l i d a t e  t h e  m i c r o a r r a y  r e s u l t s ,  w e  c o n d u c t e d  
qRT-PCR analysis on 5 genes including APP, 
DNAJC19, ESR2, SLC1A6 and SLC9A6 because of 
the highest (SLC9A6) and lowest (DANJC19) ex-
pression levels in PTSD BA46 or because of their 
known relevance to neuropsychiatric disorders 
(APP, EST2 and SLC1A6). The results showed that 
the relative mRNA levels of these genes measured 
by qRT-PCR were essentially in agreement with the 
data detected by microarray experiments (Fig. 3). 
Specifically, 11 of 12 (92%) of expression changes 
were consistent between these two methods for APP, 
9 of 12 (75%) for SLC9A6, and 8 of 12 (67%) for 
DNAJC19, SLC1A6 and ESR2. The discrepant data 
were randomly distributed among the genes and 
samples tested (Fig. 3), indicating the absence of a 
systematic error in these two methods. Thus, we 
subjected all the 119 dysregulated genes to analysis 
of a systems biology including the pathway, ontol-
ogy and network.   
The mitochondrial dysfunction and oxidative 
phosphorylation pathways contained the highest 
number of dysregulated genes. To see functional Int. J. Biol. Sci. 2008, 4 
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relationships, we conducted the canonical pathway 
analysis on 119 dysregulated genes. The results 
showed that out of 94 canonical pathways, 16 (17.0%) 
contained a significant number of dysregulated genes 
per pathway, of which 10 were listed in Figure 4A. The 
mitochondrial dysfunction pathway contained 8 
(4.8%) dysregulated genes (p=6.61x10-6) including 
upregulated APP, CAT, NDUFA10 and UCP2 and 
downregulated COX8A, NDUFB5, NDUFS2 and 
PDHA1. The oxidative phosphorylation pathway had 
6 (3.8%) dysregulated genes (p=9.04x10-4) including 
upregulated ATP5C1 and NDUFA10 and downregu-
lated ATP5E, COX8A, NDUFB5 and NDUFS2. The 
citrate cycle pathway had 3 (5.1%) dysregulated genes 
(p=1.71x10-3) including upregulated IDH3B and 
downregulated CS and SUCLG1. The methane me-
tabolism pathway contained 2 (3.1%) dysregulated 
genes (p=5.38x10-3) including upregulated CAT and 
downregulated MPO. The ubiquinone biosynthesis 
pathway had 3 (2.9%) dysregulated genes (p=1.11x10-2) 
including upregulated NDUFA10 and downregulated 
NDUFB5 and NDUFS2. The ERK/MARK signaling 
pathway included upregulated H3F3A, PPP2R1B, 
PRKCD and TLN2, and downregulated PRKAR2B 
(n=5 [2.8%], p=1.18x10-2). The propanoate metabolism 
pathway had upregulated ACAD8 and ACADL and 
downregulated SUCLG1 (n=3 [2.4%], p=1.21x10-2). The 
xenobiotic metabolism pathway contained upregu-
lated CAT, HSP90AB1, PPP2R1B and PRKCD and 
downregulated ALDH18A1 and MGST1 (n=6 [2.4%], 
p=1.28x10-2). The valine, leucine and isoleucine deg-
radation pathway contained upregulated ACAD8, 
ACADL and HMGCL (n=3 [2.8%], p=1.38x10-2). The 
pyruvate metabolism pathway had downregulated 
AKR1B1, HAGH and PDHA1 (n=3 [2.1%], p=2.05x10-2) 
(Fig. 4A).   
 
Fig. 3.  The consistency in RNA levels measured by mi-
croarray and qRT-PCR. Relative RNA levels of 5 genes were 
measured and analyzed by both microarray and qRT-PCR ex-
periments. The arrows indicate obvious inconsistent results 
between these two experiments. Out of these 5 genes in 12 
tissues compared, 8 of 12 (66.7%) are consistent for DNAJC19, 
SLC1A6 and ESR2, 11 of 12 (92%) for APP, and 9 of 12 (75%) 
for SLC9A6. PM: mean and SD of PTSD cases; NM: mean and 
SD of non-PTSD controls. 
 Int. J. Biol. Sci. 2008, 4 
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Fig. 4. The bar graphs indicate canonical pathways and neuropsychiatric and systemic disorders associated with dysregulated genes 
in the PTSD DLPFC BA46. (A) 10 canonical biochemical and molecular biology pathways with significantly (p<0.05, Fisher’s 
Exact Test) dysregulated genes, in the PTSD DLPFC BA46 group (P1, P2, P3, P5, P6 and N2) in comparison to the non-PTSD 
controls (N1, N3, N4, N5, N6 and P4). The ratio is calculated as the number of genes in a given pathway divided by a total number of 
genes that make up that pathway. The mitochondrial dysfunction pathway contains 8 (4.8%) dysregulated genes (p=6.61x10
-6) 
including upregulated APP, CAT, NDUFA10 and UCP2 and downregulated COX8A, NDUFB5, NDUFS2 and PDHA1. (B) Six 
categories of abnormalities in which the significant (p<0.05, Fisher’s Exact Test) number of the dysregulated genes in the PTSD 
DLPFC BA46 are known to involve, by searching the literature in the NCBI PUBMED, DAVID, OMIM and Ingenuity databases. 
Red: upregulation; green downregulation. Int. J. Biol. Sci. 2008, 4 
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46 dysregulated genes were mapped to neuro-
logical diseases and other systemic disorders. To see 
phenotypes involved, we performed mapping of all 
119 dysregulated genes to known human diseases and 
disorders. The results revealed that 35 dysregulated 
genes had known roles in a variety of neurological 
diseases (28 genes) and other systematic disorders in-
cluding endocrine (14 genes), genetics (11 genes), me-
tabolism (12 genes) and psychology (6 genes). The 
number of these dysregulated genes were all statisti-
cally significant (p<0.05). In addition, 17 (61%) of the 28 
genes that were mapped to neurological diseases were 
known to play a role in survival and apoptosis of a cell. 
Moreover, a total of 30 dysregulated genes were 
mapped to the cell survival-apoptosis category (Fig. 
4B). Many of these genes are involved in multiple ab-
normalities, suggesting that PTSD is a neurological 
and systemic disorder.   
30 dysregulated genes have known roles in 
neurological and psychiatric diseases. Table 2 lists 30 
PTSD-dysregulated genes that have been described to 
play a pathogenic role in various neurological diseases 
and psychiatric disorders. Upregulated APP induces 
changes in nitric oxide production and mitochondrial 
activity, leading to apoptosis [31], which have been 
implicated in amyloidosis [32;33], neurodegeneration 
[34], Alzheimer's disease [35;36] and Down syndrome 
[37]. Considering the role of myeloperoxidase (MPO) 
in modulating vascular inflammatory responses and 
transporting molecules as well as its incapability of 
clearing up amyloid when mutated [38-40], MPO 
downregulation may lead to regional accumulation of 
amyloid, resulting in mitochondrial dysfunction and 
cell death. Peptidylprolyl isomerase D (PPID) sup-
presses apoptosis via a mitochondrial hexokinase 
II-dependent mechanism and its decreased expression 
has been associated with corticobasal degeneration 
characterized by nerve cell loss and atrophy  [41]. 
Dysregulation of genes with known functions as neu-
rotransmitters in synaptic vesicles (SLC1A6 and 
VAMP1) and cell adhesion (PECAM1, CDH13 and 
SPG7) are related to diseases in the central nervous 
system. Dysregulation of these genes might reduce 
synaptic communication, and jeopardize cell-to-cell 
interactions and/or cell-to-matrix adhesion. These are 
but a few examples (Table 2). 
Table 2. 30 Dysregulated Genes in the PTSD DLPFC BA46 and Neuropsychiatric Disorders* 
No. Gene  Name    Change  Role  Neuropsychiatric  Disorder 
1  Bcl2  B-cell CLL/lymphoma 2  -0.49 (0.005) Neurodegeneration 
2  PPID  Peptidylprolyl isomerase D  -0.94 (0.002) Neurodegeneration  
3  APP  Amyloid beta A4 precursor protein  1.05 (0.002)  Amyloidosis; Neurodegeneration; Alzheimer 
disease; Down syndrome  
4 MPO  Myeloperoxidase  -0.36  (0.017)
Mitochondrial 
dysfunction and 
cell death  
Alzheimer disease 
5  CASP4  Caspase 4, apoptosis-related cysteine 
peptidase 
-0.41 (0.017) Alzheimer disease 
6  CD59  CD59 molecule, complement regulatory 
protein 
-0.57 (0.041)
Cell death 
Cerebral infarction 
7  SLC25A6  Solute carrier family 25 (mitochondrial 
carrier; adenine nucleotide translocator), 
member 6 
-0.47 (0.036) Mitochondrial 
transporter 
Parkinson disease 
8  ALDH18A1 Aldehyde dehydrogenase 18A1  -0.57 (0.032) Neurodegeneration 
9  PDHA1  Pyruvate dehydrogenase alpha 1    -0.79 (0.003) Severe neurological dysfunction and growth 
retardation 
10  AKR1B1  Aldo-keto reductase family 1 member B1  -0.48 (0.027) Diabetic retinopathy 
11  MPST  Mercaptopyruvate sulfurtransferase  1.02 (0.0003)
Mitochondrial en-
zyme 
 
Bipolar affective disorder 
12  NDUFS2  NADH dehydrogenase (ubiquinone) Fe-S 
protein 2  
-0.71 (0.004) Mitochondrial encephalomyopathy  
13  SURF1  Surfeit 1  0.95 (0.004)  COX-deficient Leigh syndrome  
14  ATP5C1  ATP synthase, H+ transporting, mito-
chondrial F1 complex, gamma polypep-
tide 1 
0.60 (0.007) 
Mitochondrial oxi-
dative phosphory-
lation  
Bipolar affective disorder 
15  SLC1A6  Solute carrier family 1 (high affinity as-
partate/glutamate transporter), member 6
-1.06 
(0.0002) 
Schizophrenia  
 
16  VAMP1  Vesicle-associated membrane protein 1 
(synaptobrevin 1) 
-0.88 (0.010)
Neurotransmitter 
Neurological lethal-wasting; Schizophrenia 
17  PECAM1  Platelet/endothelial cell adhesion mole-
cule  
-0.55 (0.006) Multiple sclerosis, ischaemic stroke; Alz-
heimer disease 
18  CDH13  Cadherin 13  0.71 (0.011)  Aggregation of brain cancer cell line; inhibi-
tion of cancer cell growth; broadly expressed 
in central nervous system 
19  SPG7  Spastic paraplegia 7  -0.46 (0.042)
Cell adhesion 
Autosomal recessive spastic paraplegia 
20 CAT  Catalase  0.61 
(0.048) 
Inhibition of neurite outgrowth 
21 UCP2  Uncoupling  protein  2  0.58 
(0.041) 
Stress response and 
reactive oxygen 
species  Schizophrenia Int. J. Biol. Sci. 2008, 4 
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22  HSPA1A  Heat shock 70kDa protein 1A  0.90 (0.003)  Neurodegeneration 
23  CRYAB  Crystallin, alpha B  -0.61 (0.046) Neurodegenerative disease 
24  HSPD1  Heat shock 60kDa protein 1 (chaperonin)  0.89 (0.002) 
Stress response and 
protein folding 
Spastic paraplegia 
25  PPP2R1B  Protein phosphatase 2 (formerly 2A), 
regulatory subunit A, beta isoform 
0.58 (0.004)  Protein phos-
phatase 
Alzheimer disease 
26  PRKAR2B  Protein kinase, cAMP-dependent, regula-
tory, type II, beta 
-0.46 (0.042) Cataleptic behavior 
27  PRKCD  Protein kinase C, delta  0.61 (0.008) 
Protein kinase 
Parkinson disease model and its treatment  
28  FABP3  Fatty acid binding protein 3  -0.55 (0.049) Fatty acid metabo-
lism  
Down syndrome and Alzheimer's disease 
29  SERPINA3  Serpin peptidase inhibitor clade A mem-
ber 3 
-0.35 (0.011) Protease inhibitor  Parkinson disease; Alzheimer disease 
30  ESR2  Estrogen receptor 2 (ER beta)  0.98 (0.025)  transcription factor Alzheimer disease; Anorexia nervosa; Major 
depressive disorder (MDD) 
* Change: fold changes of the average mRNA levels of a gene in the PTSD BA46 vs. non-PTSD controls; the numbers outside of parentheses 
indicate the fold changes and those in the parentheses are p-values. 
 
Networks of 54 dysregulated genes involved in 
neuron function and survival and 7 protein targets 
for neuropsychiatric drugs: To reveal complex inter-
actions among dysregulated genes and to identify gene 
targets for the central nervous system drugs, we 
mapped 54 dysregulated genes to molecular networks. 
These genes were selected for analysis because of their 
obvious relevance to neurological diseases, psycho-
logical disorders, psychiatric disorders, and stress re-
sponse in the central nervous system. The results re-
vealed interactive networks with a total of 75 molecu-
lar elements that maintain neuronal function and sur-
vival. Within these networks, 27 (36%) genes were 
upregulated; 27 (36%) genes were downregulated; and 
21 (28%) elements appear to be unchanged (Fig. 5). 
These data strongly suggest molecular and cellular 
abnormalities in neuronal function and survival in 
PTSD DLPFC BA46.  
Importantly, 7 gene products within the neuronal 
function-survival networks were identified as known 
targets of drugs that are used for neurological diseases, 
psychological and/or behavioral disorders, including 
APP as a target for Bapineuzumab (AAB-001), VAMP1 
for Dysport, SLC1A6 for Riluzole, ESR2 for 
17β-estradiol (agonist) and Tamoxifen (antagonist), 
PRKCD for Tamoxifen and rottlerin, PP2A for Okadaic 
Acid and Fostriecin, and UCP2 for MPTP 
(1,2,3,6-methyl-phenyl-tetrahydropyridine).  
Discussion 
Human brain DLPFC including BA46 is involved 
in regulation of working memory and preparation and 
selection of fear responses and has been correlated 
with structural and functional alterations and treat-
ment response of patients with PTSD [9-13]. However, 
the underlying cellular and molecular mechanisms are 
unknown. In this study, we applied human mito-
chondria-focused cDNA microarrays (hMitChip3) to 
PTSD brain samples and have successfully identified 
expression signatures, canonical pathways, molecular 
networks and drug targets of neurological disease- and 
psychological/psychiatric disorder-related genes that 
are dysregulated in the DLPFC BA46. Our results in-
dicate mitochondrial dysfunction involved in neuronal 
function and survival in the DLPFC BA46 and may 
prove useful for development of methods for diagno-
sis, prevention and treatment of PTSD. 
Unsupervised clusters of 12 DLPFC BA46 RNA 
samples based solely on expression similarities of in-
formative 800 mitochondria-focused genes clearly dis-
tinguish the PTSD brains from the controls. The iden-
tification of 119 (p<0.05, ±≥1.25) and 42 (p<0.05, ±≥1.60) 
dysregulated genes provides candidates for qRT-PCR 
validation and for subsequent functional studies. The 
clustering signatures of these genes may facilitate fur-
ther development of methods and tools for forensic 
diagnosis of PTSD. Our approach has generated in-
formative results partially because of our accurate 
dissection of brain DLPFC BA46 gray matter, and par-
tially because of the utilization of our hypothe-
sis-driven mitochondria-focused cDNA microarrays. 
However, we cannot explain why the samples P4 and 
N2 had expression profiles different from their clinical 
classification. Due to a small sample size, P4 and N2 
were kept in the groups based on their gene expression 
rather than a clinical diagnosis because the former 
might be more objective than the latter. We would like 
t o  r e p e a t  t h e  s t u d y  w h e n  m o r e  P T S D  a n d  c o n t r o l  
specimens become available in order to improve the 
molecular classification of PTSD. The subsequent ex-
periments should examine both mRNA and protein 
levels in the DLPFC BA46, as well as other 
PTSD-related brain regions such as medial and ventral 
PFC, hippocampus, and amygdala [6;7;42]. 
 Int. J. Biol. Sci. 2008, 4 
 
232
 
Fig. 5. The molecular networks for neuron function and survival. The networks have a total of 75 elements including 27 (36%) 
upregulated genes, 27 (36%) downregulated genes and 21 (28%) unchanged ones. Twenty-one elements in white color include 7 
genes present and 11 genes absent in the hMitChip3 microarray, and 3 small molecules. The symbols in Legend illustrate the net-
works. The genes in the blue boxes are the known targets for neuropsychiatric drugs. For example: the ESR2 is a target of 
17β-estradiol or related ligands. The APP is a target for Bapineuzumab (AAB-001) that is currently used for the Phase 3 clinical 
trials for the treatment of patients with Alzheimer’s disease. The ESR2 is a target for Tamoxifen that is used for the treatment of 
mania in patients with bipolar disorder. The PRKCD is a target for both Tamoxifen, and rottlerin that has been used in preclinical 
treatment of Parkinson’s disease. The PP2A is a target for Fostriecin that antagonize dopamine activities. The VAMP1 is a target of 
the neurotoxin protein Dysport that is used in minute doses to treat painful muscle spasms. The SLC1A6 is a target of Riluzole used 
to treat amyotrophic sclerosis. The UCP2 is a target for protection of dopaminergic neurons from oxidative stress caused by 
1,2,3,6-methyl-phenyl-tetrahydropyridine (MPTP) toxicity. 
 
The mitochondria-mediated cellular and mo-
lecular response to stress in the central nervous system 
of patients with PTSD is the key part of our hypothesis 
because mitochondria are at the center of a cellular 
response to stress [14;15]. Study of mitochondrial 
function is inevitable and our application of the mito-
chondria-focused cDNA microarrays to PTSD is just 
the beginning. Mitochondrial function in the brain is of 
particular importance because of its high energy de-
mand. Although human brain represents only 2% of 
body weight, it receives 15% of the body’s cardiac 
output, and uses 20% of total body oxygen. These high 
level oxygen and energy requirements are continuous 
and imply that even brief periods of oxygen or glucose Int. J. Biol. Sci. 2008, 4 
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deprivation may impair neuron function and even 
result in neuron death. Our demonstration that a 
highly significant number of oxidative phosphoryla-
tion genes were dysregulated in the PTSD brain BA46 
strongly suggests the presence of at least energy defi-
ciency in this brain region. Our findings support the 
postulation that mitochondria-focused and 
stress-responsive genes may play a key role in the 
pathogenesis of PTSD, although the specific impact of 
these dysregulated genes and pathways on brain 
function remains to be determined. 
The identification and validation of the dysregu-
lated genes enhances our understanding of the cellular 
and molecular mechanisms underlying the patho-
physiology of PTSD. The genes listed in Table 2 are 
critical to the BA46 neuronal functions including sur-
vival and apoptosis, carbohydrate and lipid metabo-
lism, ATP and ROS production, synthesis and trans-
port of neurotransmitter, mitochondrial and nuclear 
DNA expression, and protein phosphorylation and 
dephosphorylation as well as folding and degradation. 
Because homeostasis of these mitochondrial functions 
is vital for neuronal function and survival, the pres-
ence of a hundred consistently dysregulated genes in 
the PTSD DLPFC BA46 implies a pathological role. In 
addition, more genes were downregulated than those 
upregulated (63 vs. 56 in Supplemental Table 1 and 18 
vs. 12 in Table 2). Moreover, some upregulated genes 
play a degradative or negative role such as proapop-
tosis (e.g., APP), reduction of ATP synthesis (e.g., 
UCP2) and protein breakdown (e.g., HSPA1A). Taken 
together, functional impairment and atrophy in the 
PTSD DLPFC BA46 might be a consequence of these 
dysregulated genes. Thus, the neurons in the PTSD 
DLPFC BA46 may be unable to regulate working 
memory and preparation and selection of healthy re-
sponses to fear or may even send abnormal signals to 
their downstream executive neurons such as those in 
the hippocampus and/or amygdala. Our molecular 
insight in the PTSD DLPFC BA46 pathogenesis is 
reminiscent of the neurocircuitry model by Bremner 
[43] and Rauch et al [42] that the fear extinction ab-
normalities in PTSD are characterized by exaggerated 
amygdala responses and deficiency in ventral/medial 
PFC and hippocampus. Therefore, our systems biology 
results appear not only to extend the neurocircuitry 
model to brain DLPFC BA46, but they also provide 
genes and proteins that should be further investigated 
for better understanding of the molecular pathogenesis 
of PTSD. 
Seven protein targets for neuropsychiatric drugs 
are present in the neuronal function-survival networks 
in human brain DLPFC BA46. In addition of dysregu-
lation of 72% (54/75) genes in these networks, many 
dysregulated genes are associated with multiple neu-
ropsychiatric conditions such as Alzheimer’s disease, 
Parkinson’s disease, Schizophrenia, and Major De-
pressive Disorder (MDD), Down syndrome, attention 
disorders and mood disorders (Table 2). Obviously, 
modulations of these genes with drugs would affect 
neuropsychiatric functions of the neurons in human 
DLPFC BA46. For example, the APP is a target for the 
immunotherapeutic drug Bapineuzumab that is cur-
rently used for the Phase 3 clinical trials for the treat-
ment of patients with Alzheimer’s disease [44]. The 
ESR2 is a target for 17β-estradiol (agonist) and Ta-
moxifen (antagonist). Beside the treatment of estro-
gen-receptor positive breast cancer, Tamoxifen is used 
to treat mania in patients with bipolar disorder, 
probably by blocking PRKCD [45]. The PRKCD is also 
a target for rottlerin used in preclinical study of Park-
inson’s disease [46]. The PP2A is a target for Fostriecin 
that antagonizes dopamine activities [47]. The UCP2 is 
a target for protection of dopaminergic neurons from 
oxidative stress caused by 
1,2,3,6-methyl-phenyl-tetrahydropyridine (MPTP) 
toxicity [48]. However, whether these drugs and re-
lated targets might be useful for prevention and 
treatment of PTSD is interesting and deserves further 
studies.  
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